HansBiomed Statistics
Total Valuation
HansBiomed has a market cap or net worth of KRW 117.40 billion. The enterprise value is 148.76 billion.
Market Cap | 117.40B |
Enterprise Value | 148.76B |
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025.
Earnings Date | Aug 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
HansBiomed has 12.99 million shares outstanding. The number of shares has increased by 7.33% in one year.
Current Share Class | 12.99M |
Shares Outstanding | 12.99M |
Shares Change (YoY) | +7.33% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 26.95% |
Owned by Institutions (%) | 0.71% |
Float | 7.04M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.39 |
PB Ratio | 1.80 |
P/TBV Ratio | 1.82 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 75.78, with an EV/FCF ratio of -54.05.
EV / Earnings | -22.46 |
EV / Sales | 1.76 |
EV / EBITDA | 75.78 |
EV / EBIT | n/a |
EV / FCF | -54.05 |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 0.66.
Current Ratio | 1.08 |
Quick Ratio | 0.50 |
Debt / Equity | 0.66 |
Debt / EBITDA | 7.33 |
Debt / FCF | -15.70 |
Interest Coverage | 0.34 |
Financial Efficiency
Return on equity (ROE) is -10.22% and return on invested capital (ROIC) is 0.36%.
Return on Equity (ROE) | -10.22% |
Return on Assets (ROA) | 0.31% |
Return on Invested Capital (ROIC) | 0.36% |
Return on Capital Employed (ROCE) | 0.82% |
Revenue Per Employee | 320.74M |
Profits Per Employee | -25.18M |
Employee Count | 263 |
Asset Turnover | 0.68 |
Inventory Turnover | 1.19 |
Taxes
In the past 12 months, HansBiomed has paid 1.67 billion in taxes.
Income Tax | 1.67B |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.21% in the last 52 weeks. The beta is 0.83, so HansBiomed's price volatility has been lower than the market average.
Beta (5Y) | 0.83 |
52-Week Price Change | -27.21% |
50-Day Moving Average | 7,783.60 |
200-Day Moving Average | 8,361.50 |
Relative Strength Index (RSI) | 58.15 |
Average Volume (20 Days) | 46,223 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HansBiomed had revenue of KRW 84.36 billion and -6.62 billion in losses. Loss per share was -510.64.
Revenue | 84.36B |
Gross Profit | 52.56B |
Operating Income | 612.84M |
Pretax Income | -5.37B |
Net Income | -6.62B |
EBITDA | 5.89B |
EBIT | 612.84M |
Loss Per Share | -510.64 |
Balance Sheet
The company has 11.75 billion in cash and 43.19 billion in debt, giving a net cash position of -31.45 billion or -2,421.46 per share.
Cash & Cash Equivalents | 11.75B |
Total Debt | 43.19B |
Net Cash | -31.45B |
Net Cash Per Share | -2,421.46 |
Equity (Book Value) | 65.21B |
Book Value Per Share | 5,028.31 |
Working Capital | 4.54B |
Cash Flow
In the last 12 months, operating cash flow was -553.02 million and capital expenditures -2.20 billion, giving a free cash flow of -2.75 billion.
Operating Cash Flow | -553.02M |
Capital Expenditures | -2.20B |
Free Cash Flow | -2.75B |
FCF Per Share | -211.91 |
Margins
Gross margin is 62.30%, with operating and profit margins of 0.73% and -7.85%.
Gross Margin | 62.30% |
Operating Margin | 0.73% |
Pretax Margin | -6.36% |
Profit Margin | -7.85% |
EBITDA Margin | 6.98% |
EBIT Margin | 0.73% |
FCF Margin | n/a |
Dividends & Yields
HansBiomed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.33% |
Shareholder Yield | n/a |
Earnings Yield | -5.64% |
FCF Yield | -2.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
HansBiomed has an Altman Z-Score of 1.78 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.78 |
Piotroski F-Score | 5 |